Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal Q3 revenue rises 10% to $863 million; GAAP net loss of $22 million

Mixed Impact 4 of 5 earnings

Amneal reported third-quarter 2026 net revenue of $863 million, up 10%, and Adjusted EBITDA of $207 million, up 30%, but swung to a GAAP net loss of $22 million from net income a year earlier, driven by acquisition and integration costs and a higher tax provision. The company raised its full-year 2026 revenue, Adjusted EBITDA and adjusted EPS guidance, while lowering its operating cash flow guidance, which it attributed to higher inventory levels.

Key points

  • Q3 2026 net revenue was $863 million, up from $785 million in Q3 2025; Adjusted EBITDA was $207 million, up 30%.
  • GAAP net loss attributable to Amneal was $22 million, or $(0.06) per diluted share, compared with net income of $2 million a year earlier; adjusted diluted EPS was $0.26, up 53% from $0.17.
  • Full-year 2026 net revenue guidance rose to $3.15 billion to $3.25 billion from $3.10 billion to $3.20 billion; Adjusted EBITDA guidance rose to $800 million to $815 million from $750 million to $780 million.
  • Operating cash flow guidance was lowered to $325 million to $375 million from $350 million to $400 million, reflecting working capital, including higher inventory levels.

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:07 AM ET
Accession number0001723128-26-000035

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.